En studie som visar att signifikant fler (63%) patienter fick barn när EmbryoGlue® användes, jämfört med kontrollgruppen, presenterades vid den pågående ESHRE-konferensen i Stockholm. Vitrolifes patenterade medium EmbryoGlue® används vid återförande av embryon i samband med assisterad befruktning.
We have now shown that EmbryoGlue® results in more babies being born compared with traditional products, irrespective of the day when the embryos are reintroduced, says Dr. Basak Balaban, who works at the American Hospital in Istanbul, Turkey.
The independent Cochrane report has previously shown that EmbryoGlue® has a positive effect on pregnancy frequency.
The study results were presented at the annual ESHRE conference (European Society of Human Reproduction and Embryology) that is being held in Stockholm this year. The conference started on Sunday and has brought together approximately 8,000 delegates from all over the world.
EmbryoGlue® is a patented product with a unique composition that includes hyaluronic acid and it is similar to the natural environment in the womb. The components that it contains provide the embryo with the necessary nutrients and sources of energy and make it easier for the reintroduced embryos to attach to the endometrium and develop into a foetus.
July 5, 2011
Kontaktpersoner: VD Magnus Nilsson, telefon 031-721 80 61 Ekonomi- och informationschef Anne-Lie Sveder, telefon 031-721 80 13
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes. Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered inGothenburg,Sweden, and there are subsidiaries inUSA,Australia,France,Italy,United KingdomandJapan. Production facilities are located inSwedenand theUSA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap. ______________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com (http://www.vitrolife.com/)